Scientific and Clinical Advisors
Dr. Bailes is a medical oncologist with substantial experience in legislation, public policy and advocacy, as well as the business aspects of the practice of oncology and medicine. Dr. Bailes has served in various executive leadership capacities for the American Society of Clinical Oncology (ASCO), including terms as President, Interim Executive Vice President and Chief Executive Officer, and Chair of the ASCO Government Relations Council. He has also served as the Executive Vice President of Clinical Affairs for US Oncology, Inc. Prior to that, Dr. Bailes was Executive Vice President and National Medical Director of Physician Reliance Network, Inc (PRN), one of the corporate predecessors to US Oncology. Dr. Bailes has many years of experience in the practice of oncology in the private sector, he is a partner in Texas Oncology, P.A., the largest oncology practice group in the country, and he was a founding member of PRN. Dr. Bailes received his medical degree from the University of Texas Southwestern Medical School at Dallas, followed by his internship and residency at Parkland Memorial Hospital in Dallas. He completed his Medical Oncology/Hematology Fellowship at the University of Texas Health Science Center in San Antonio.
Dr. Demetri is the Quick Family Chair in Medical Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He serves as an Associate Director for Clinical Sciences at the NCI-designated consortium Dana-Farber/Harvard Cancer Center, as well as a Co-Director (with cell biologist Joan Brugge, PhD) of the Ludwig Center at Harvard. His work was critical to the development of Gleevec and other kinase-targeted therapies in gastrointestinal stromal tumors (GIST) as one of the first examples of targeted cancer therapy for a treatment-resistant solid tumor.
Gary H. Lyman M.D., MPH, FASCO is co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR) at the Fred Hutchinson Cancer Research Center where he is a member of the Public Health Sciences and Clinical Research Divisions. He is also professor of medicine at the University Of Washington School Of Medicine, Adjunct Professor of Public Health and Pharmacy and a member of the Breast Cancer Program at the Seattle Cancer Care Alliance. Dr Lyman is a medical oncologist and hematologist with research interests that include comparative effectiveness and outcomes research related to targeted therapies and biomarkers, personalized cancer supportive care, efforts to integrate health economics into evidence-based medicine, health policy, and advanced methods of evidence synthesis to uncover patterns of cancer treatment measures of effectiveness and toxicity in real world settings and the impact of health disparities on the quality of cancer care.
In addition to his training in internal medicine at UNC-Chapel Hill and hematology/oncology at Roswell Park Cancer Institute, Lyman was a postdoctoral fellow in biostatistics at the Harvard School of Public Health. He previously served as Chief of Medicine at the Moffitt Cancer Center and Director of Comparative Effectiveness and Outcomes Research at Duke University before assuming his current position. Lyman is a Fellow of the American Society of Clinical Oncology and serves on its board of directors, is editor-in-chief of Cancer Investigation, and serves on the editorial board of the Journal of Clinical Oncology, Journal of global Oncology, and several other professional publications. He has authored or edited more than 15 books and more than 500 scientific articles.
Donald P. McDonnell, Ph.D., is the Glaxo-Wellcome Professor of Molecular Cancer BiologyDonald P. McDonnell, Ph.D., is the Glaxo-Wellcome Professor of Molecular Cancer Biology and Chairman of the Department of Pharmacology and Cancer Biology at Duke University School of Medicine. In addition, he serves as Co-Director of the Women’s Cancer Program within the Duke Cancer Institute.
Dr. McDonnell obtained a Degree in Biochemistry from the National University of Ireland (Galway) in 1983 and a PhD from the Baylor College of Medicine, Houston, TX, in 1988, under the mentorship of Dr. Bert O’Malley. After three years in industry at SmithKline and Ligand Pharmaceuticals, he moved to Duke where his work has focused on the genetic and pharmacological dissection of the nuclear receptor signal transduction pathways. The insights from this work have led to the discovery and development of novel estrogen and androgen receptor modulators, some of which have advanced to the clinic and are being evaluated as treatments for breast and prostate cancers and a variety of endocrinopathies.Dr. McDonnell has received numerous investigator awards; the most notable being the Roy E. Greep, Weitzman, and Ernst Oppenheimer Awards from the Endocrine Society, ASPET’s John J. Abel Award, the Pharmacia-ASPET Award for Experimental Therapeutics, the NAMS SERM Research Award and the Robert Ruffolo lifetime achievement award in pharmacology. He is an Honorary Fellow of the Royal College of Physicians, Ireland. Recently he was elected as a member of the National Academy of Medicine. Dr. McDonnell has published over 300 articles on the molecular pharmacology of nuclear hormone receptors. Currently, he is deputy editor of Oncogene, and sits on the editorial board of several journals.
Dr. Seth Rudnick has extensive expertise in oncology, drug discovery and development, and healthcare investments. He is recently retired from Canaan Partners, where he built the global venture capital firm's capability in biopharmaceutical investing. Prior to joining Canaan, he was the chief executive officer and chairman of CytoTherapeutics, a developer of cell therapies to combat chronic diseases. He also helped start and led the development of Ortho Biotech, a division of Johnson & Johnson. Earlier in his career, Dr. Rudnick worked at Shering-Plough and directed pharmaceutical development efforts at Biogen.
Dr. Rudnick was a Yale Fellow in medical oncology where he was also a Robert Wood Johnson Scholar. He earned his medical degree at the University of Virginia and holds a BA in history from the University of Pennsylvania. He is a Clinical Professor of Medicine at the University of North Carolina, Chapel Hill, teaching and advising faculty members on biotechnology issues. He also currently serves as the chariman of Liquidia Technologies, Drug innovation Ventures at Emory (DRIVE) and Meryx, and serves on the boards of Vaxinnate, POZEN and Square 1 Financial.
Dr. Shapiro received his PhD in 1987 and his MD in 1988 from Cornell University, followed by postgraduate training in internal medicine at Beth Israel Hospital, Boston, where he served as chief medical resident. He completed a fellowship in medical oncology at Dana-Farber Cancer Institute, during which he investigated the role of cell-cycle-related proteins in lung cancer. He joined the Dana-Farber faculty in 1994. He is currently an Associate Professor of Medicine at Harvard Medical School and the Dana-Farber. He serves as the Director of the Early Drug Development Center, where Phase 1 and proof-of-mechanism trials are conducted. He is also a member of Dana-Farber’s Thoracic Oncology Program and a member of the Dana-Farber/Harvard Cancer Center SPORE (Specialized Program of Research Excellence) in Lung Cancer.
Dr. Wong obtained his MD and PhD at the Columbia University College of Physicians and Surgeons. He was trained in internal medicine at the Massachusetts General Hospital, and hematology and oncology at the Dana-Farber Cancer Institute (DFCI), both at Harvard Medical School. He is currently chief of hematology and medical oncology at the Perlmutter Cancer Center at NYU Langone Medical Center. Previously Dr. Wong was the scientific director of the Belfer Institute for Applied Cancer Science at DFCI/Harvard Medical School. He has authored more than 200 papers and 3 patents on the molecular biology of cancer and aging. He is a member of the American Society of Clinical Investigation, the nation’s oldest honor society for physician-scientists.